You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾華製藥(NVS.US)第一季度淨核心每股盈餘超市場預期 公司預計營收在中等個位數範圍內增長
格隆匯 04-26 15:57
格隆匯4月26日丨諾華製藥(NVS.US)今日公佈業績,第一季度淨收入為22.2億美元,高於上年同期的18億美元;營收從124.1億美元增長到125.3億美元;營業利潤從上年的24.2億美元增至28.5億美元;核心每股盈餘為1.46美元,高於1.44美元的市場預期。以上數據均不包括2021年剝離羅氏股份的影響。增長的來源是心臟衰竭治療藥物Entresto、多發性硬化症藥物Kesimpta和銀屑病和關節炎治療藥物Cosentyx。仿製藥部門Sandoz在經歷了疫情的逆風后繼續恢復正常,第一季度取得8%的增長。公司預計2022年底更新Sandoz戰略評估進展。公司表示,預計2022年的營收和核心營業利潤都將在中等個位數範圍內增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account